Omrix Biopharmaceuticals Inc. filed an initial public offering Wednesday to sell up to $80.5 million in common stock, according to a Form S-1 filed with the Securities and Exchange Commission. The New York commercial-stage biopharmaceutical company didn't disclose the number of shares to be offered or an estimated price range for the IPO in Wednesday's filing.

Business Online (http://www.thebusinessonline.com/DJStory.aspx?DJStoryID=20060118DN015210)